Lovastatin-induced apoptosis in human melanoma cell lines

被引:91
作者
Shellman, YG
Ribble, D
Miller, L
Gendall, J
VanBuskirk, K
Kelly, D
Norris, DA
Dellavalle, RP
机构
[1] Univ Colorado, Ctr Hlth Sci Fitzsimons, Dept Dermatol, Aurora, CO 80045 USA
[2] Dept Vet Affairs Med Ctr, Dermatol Sect, Denver, CO 80220 USA
[3] Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA
关键词
isoprenylation; melanoma; statin;
D O I
10.1097/00008390-200504000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The cholesterol-lowering medications, statins, inhibit cellular proliferation and induce apoptosis in an array of cancer cell lines, including melanoma. We investigated the apoptotic mechanism of lovastatin on human melanoma cell lines in vitro. The cytotoxicity of statins on multiple cell lines was examined by Cell Titer 96 (TM) Aqueous One solution cell proliferation assay (MTS assay). Apoptosis was assayed by ethidium bromide and acridine orange morphologic assays, an Annexin V apoptosis detection kit and active caspase 3 assays. Farnesyl pyrophosphate and geranylgeranyl pyrophosphate add-back experiments were performed to better define the molecular mechanisms mediating lovastatin cytotoxicity. Lovastatin caused cytotoxicity in human and murine melanoma cells, but did not induce toxicity in an epidermoid carcinoma cell line A431. For human melanoma cells, lovastatin precipitated cell rounding, increased the percentage of apoptotic cells detected by ethidium bromide and acridine orange staining and by the Annexin V apoptosis detection kit, and resulted in a 50-fold increase in active caspase 3, corroborating that lovastatin induced apoptosis. Adding back geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate, reversed the effects of lovastatin in A375 cells. Of the five statins tested, pravastatin was least effective in killing melanoma
引用
收藏
页码:83 / 89
页数:7
相关论文
共 24 条
[1]   Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac [J].
Agarwal, B ;
Rao, CV ;
Bhendwal, S ;
Ramey, WR ;
Shirin, H ;
Reddy, BS ;
Holt, PR .
GASTROENTEROLOGY, 1999, 117 (04) :838-847
[2]  
Agarwal B, 1999, CLIN CANCER RES, V5, P2223
[3]   ATHEROSCLEROSIS - SCAVENGING FOR RECEPTORS [J].
BROWN, MS ;
GOLDSTEIN, JL .
NATURE, 1990, 343 (6258) :508-509
[4]   Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors [J].
Chong, PH .
ANNALS OF PHARMACOTHERAPY, 2002, 36 (12) :1907-1917
[5]  
COHEN GM, 1993, J IMMUNOL, V151, P566
[6]  
Collisson EA, 2003, MOL CANCER THER, V2, P941
[7]   Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells [J].
Collisson, EA ;
Carranza, DC ;
Chen, IY ;
Kolodney, MS .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (05) :1172-1176
[8]  
DUKE RC, 1995, CURRENT PROTOCOLS IM, V1
[9]  
DUKE RC, 1991, CURRENT PROTOCOLS IM
[10]   Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism [J].
Feleszko, W ;
Mlynarczuk, I ;
Olszewska, D ;
Jalili, A ;
Grzela, T ;
Lasek, W ;
Hoser, G ;
Korczak-Kowalska, G ;
Jakóbisiak, M .
INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (01) :111-118